glp 1 drugs alternative equivalency chart Promising New Science on Weight Loss Drug Alternatives A new FDA-approved obesity pill

Eur J Pharmacol 2019;864:172715.ArticlePubMed 108

(3) Drug Delivery Innovation: a

Selection of the reported result

Once stable, monitoring every three to six months is appropriate, reducing to six-monthly when control is well established

It is also in the midst of early trials for LX9851, a non-incretin obesity drug that would be a potential alternative to GLP-1s

However, no studies of head-to-head trials on the treatment of MASLD with phentermine and topiramate vs semaglutide have been published, and there have been no clinical trials to date that have directly compared the anti-obesity medications in the adolescent population